PMC8792848_01
The curve of CA199 change after tumor metastasis. The patient's CA19-9 level was measured periodically and is annotated with the dates and treatments administered. A-PTX, albumin paclitaxel; CA19-9, carbohydrate antigen 19-9; CAP, capecitabine; HCQ, hydroxychloroquine; IRI, irinotecan; SOX, S-1 plus oxaliplatin.
fmed-08-746637-g0001.jpg
PMC8792848_01_fmed-08-746637-g0001.jpg
F1
During this period, due to the increase of CA19-9 level (Figure 1), Olaparib combined with irinotecan was used for treatment from October 2018, and the disease stabilized until November 2019 (Figure 2). Due to the increase of CA19-9 (Figure 1), the patient transferred to SOX chemotherapy (oxaliplatin injection 130 mg D1 + S-1 60 mg twice a day, D1-7, Q2W) for 5 cycles from 2019-11 to 2020-1. Nevertheless, the patient's level of CA 19-9 (Figure 1) continued to increase during the first month of treatment. The CA19-9 level (Figure 1) decreased significantly, and MRI (Figure 3) indicated a 6% reduction in tumor burden by RECIST 1.1 criteria, achieving stable disease (SD).
Change in the tumor prior to, during and following olaparib therapy based on representative MRI. In October 2018, prior to olaparib therapy, MRI showed anterior abdominal wall mass and retroperitoneal mass. Continuous stable disease was observed for 12 months during olaparib (with or without irinotecan) therapy. However, the retroperitoneal mass enlarged in October 2019, meanwhile, the CA19-9 level increased dramatically. Thus, the patient was transferred to SOX chemotherapy. CA19-9, carbohydrate antigen 19-9; MRI, magnetic resonance images; SOX, S-1 plus oxaliplatin.
fmed-08-746637-g0002.jpg
PMC8792848_01_fmed-08-746637-g0002.jpg
F2
During this period, due to the increase of CA19-9 level (Figure 1), Olaparib combined with irinotecan was used for treatment from October 2018, and the disease stabilized until November 2019 (Figure 2).
Stable disease was observed during the treatment of trametinib combined with hydroxychloroquine based on MRI. MRI, magnetic resonance images.
fmed-08-746637-g0003.jpg
PMC8792848_01_fmed-08-746637-g0003.jpg
F3
The CA19-9 level (Figure 1) decreased significantly, and MRI (Figure 3) indicated a 6% reduction in tumor burden by RECIST 1.1 criteria, achieving stable disease (SD).